[go: up one dir, main page]

PE20070214A1 - Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-trifluoreometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida - Google Patents

Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-trifluoreometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida

Info

Publication number
PE20070214A1
PE20070214A1 PE2006000870A PE2006000870A PE20070214A1 PE 20070214 A1 PE20070214 A1 PE 20070214A1 PE 2006000870 A PE2006000870 A PE 2006000870A PE 2006000870 A PE2006000870 A PE 2006000870A PE 20070214 A1 PE20070214 A1 PE 20070214A1
Authority
PE
Peru
Prior art keywords
methyl
pirimidi
nilamino
imidazo
nil
Prior art date
Application number
PE2006000870A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Piotr H Karpinski
Stephanie Monnier
Jorg Brozio
Raeann Wu
Paul Allen Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070214A1 publication Critical patent/PE20070214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA A, B SUSTANCIALMENTE PURA DE LA BASE LIBRE DE LA 4-METIL-N-[3-(4-METIL-IMIDAZO-1-IL)-5-TRIFLUOROMETIL]-3-(4-PIRIDI-3-NIL-PIRIMIDI-2-NILAMINO)-BENZAMIDA CARACTERIZADA POR UN PATRON DE DIFRACCION DE POLVO POR RAYOS X , TENIENDO POR LO MENOS UN VALOR MAXIMO SELECCIONADO ENTRE 9,2; 13,1; 13,9; 16,7; 17,9; 18,4; 19,8; 24,1; 25,8. DICHO CRISTAL ES INHIBIDOR DE LA ACTIVIDAD DE LA QUINASA DE PROTEINA
PE2006000870A 2005-07-20 2006-07-19 Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-trifluoreometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida PE20070214A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
PE20070214A1 true PE20070214A1 (es) 2007-04-02

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000870A PE20070214A1 (es) 2005-07-20 2006-07-19 Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-trifluoreometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida

Country Status (43)

Country Link
US (4) US8343984B2 (es)
EP (5) EP1912973B1 (es)
JP (3) JP5289948B2 (es)
KR (3) KR20130085444A (es)
CN (2) CN102358736A (es)
AR (1) AR054846A1 (es)
AU (3) AU2006276204A1 (es)
BR (1) BRPI0613615B1 (es)
CA (1) CA2614334C (es)
CR (1) CR9657A (es)
CU (1) CU23916B1 (es)
CY (2) CY1113076T1 (es)
DK (2) DK1912973T3 (es)
EA (2) EA016856B1 (es)
EC (1) ECSP088119A (es)
ES (3) ES2623608T5 (es)
GE (1) GEP20115302B (es)
GT (1) GT200600315A (es)
HK (1) HK1116783A1 (es)
HN (1) HN2008000311A (es)
HR (2) HRP20120573T1 (es)
HU (1) HUE031791T2 (es)
IL (2) IL188189A0 (es)
JO (1) JO3308B1 (es)
LT (1) LT2284167T (es)
MA (1) MA29626B1 (es)
MX (1) MX2008000899A (es)
MY (1) MY148554A (es)
NI (1) NI200800017A (es)
NO (1) NO341930B1 (es)
NZ (1) NZ564409A (es)
PE (1) PE20070214A1 (es)
PH (1) PH12013501590A1 (es)
PL (2) PL2284167T5 (es)
PT (2) PT2284167T (es)
RS (1) RS55929B2 (es)
SG (1) SG163620A1 (es)
SI (2) SI1912973T1 (es)
SM (1) SMP200800011B (es)
TN (1) TNSN08029A1 (es)
TW (1) TWI406661B (es)
UA (1) UA94234C2 (es)
WO (1) WO2007015870A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
MX2008012903A (es) * 2006-04-07 2008-10-13 Novartis Ag Uso de inhibidores de c-src en combinacion con un compuesto de pirimidilaminobenzamida para el tratamiento de la leucemia.
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EP2240172B1 (en) 2007-12-21 2014-03-19 Novartis AG Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia
US20100016590A1 (en) 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
CA2740794A1 (en) * 2008-11-05 2010-05-14 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
WO2010100248A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
CN102647986A (zh) 2009-10-23 2012-08-22 诺瓦提斯公司 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (es) * 2010-01-15 2016-09-02
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
EP2966072A3 (en) 2010-06-21 2016-02-24 Teva Pharmaceutical Industries, Ltd. Crystalline forms of nilotinib hydrobromide, succinate, glutamate, acetate, l-malate and maleate
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (en) * 2010-11-26 2012-05-31 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
AU2012328979B2 (en) 2011-10-28 2016-04-21 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
SG11201401476TA (en) 2011-11-14 2014-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
JP2015522070A (ja) 2012-07-11 2015-08-03 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
WO2014059518A1 (en) * 2012-10-15 2014-04-24 Apotex Technologies Inc. Solid forms of nilotinib hydrochloride
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
US20160002223A1 (en) * 2013-02-21 2016-01-07 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EP2989090A4 (en) * 2013-04-24 2017-01-18 Dr. Reddy's Laboratories Ltd. Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
CA2964198C (en) * 2014-10-16 2023-03-14 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
SMT202000563T1 (it) 2016-03-14 2020-11-10 Pliva Hrvatska D O O Forem allo stato solido di sali di nilotinib
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI764186B (zh) 2018-06-15 2022-05-11 漢達生技醫藥股份有限公司 激酶抑制劑之鹽類及其組合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US12065426B2 (en) 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
WO2021155254A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
AU2021353684A1 (en) 2020-09-29 2023-06-08 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1686997B1 (en) * 2003-11-18 2009-04-15 Novartis AG Inhibitors of the mutant form of kit
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
CN103804356A (zh) 2014-05-21
MX2008000899A (es) 2008-03-18
JO3308B1 (ar) 2018-09-16
US20130023548A1 (en) 2013-01-24
UA94234C2 (uk) 2011-04-26
HN2008000311A (es) 2011-01-24
GEP20115302B (en) 2011-10-10
US8415363B2 (en) 2013-04-09
GT200600315A (es) 2007-03-19
KR20130085444A (ko) 2013-07-29
JP2013018789A (ja) 2013-01-31
EA201000145A1 (ru) 2010-06-30
ES2623608T3 (es) 2017-07-11
WO2007015870A3 (en) 2007-06-07
SI2284167T1 (sl) 2017-05-31
PL2284167T3 (pl) 2017-07-31
EP2543665A2 (en) 2013-01-09
AU2006276204A1 (en) 2007-02-08
US20140343087A1 (en) 2014-11-20
HUE031791T2 (en) 2017-08-28
US8343984B2 (en) 2013-01-01
CN102358736A (zh) 2012-02-22
AR054846A1 (es) 2007-07-18
TW200740793A (en) 2007-11-01
PL2284167T5 (pl) 2020-07-27
EA016856B1 (ru) 2012-08-30
EP2284167A2 (en) 2011-02-16
PT1912973E (pt) 2012-09-03
EP2284167B1 (en) 2017-02-01
EP2543665A3 (en) 2013-05-29
AU2012201453A1 (en) 2012-04-05
EP2284167B2 (en) 2019-11-27
EP2284167A3 (en) 2011-03-02
RS55929B2 (sr) 2020-12-31
CY1119624T1 (el) 2018-04-04
ES2648288T3 (es) 2017-12-29
KR101651288B1 (ko) 2016-08-25
US20080269269A1 (en) 2008-10-30
ECSP088119A (es) 2008-02-20
JP2009502795A (ja) 2009-01-29
AU2012201453B2 (en) 2013-09-05
PH12013501590A1 (en) 2015-09-21
CA2614334C (en) 2015-04-21
US20130165465A1 (en) 2013-06-27
SI1912973T1 (sl) 2012-08-31
CY1113076T1 (el) 2016-04-13
IL188189A0 (en) 2008-03-20
LT2284167T (lt) 2017-04-25
CU20080006A7 (es) 2011-02-24
NO20080820L (no) 2008-04-15
CR9657A (es) 2008-04-16
WO2007015870A2 (en) 2007-02-08
PL1912973T3 (pl) 2012-09-28
EP2284168A3 (en) 2011-04-13
JP5798101B2 (ja) 2015-10-21
DK1912973T3 (da) 2012-07-23
AU2012201453C1 (en) 2024-05-23
EP1912973B1 (en) 2012-06-13
TNSN08029A1 (en) 2009-07-14
IL214659A0 (en) 2011-09-27
HRP20170634T1 (hr) 2017-06-30
CU23916B1 (es) 2013-07-31
EP1912973A2 (en) 2008-04-23
HK1116783A1 (es) 2009-01-02
JP5289948B2 (ja) 2013-09-11
KR20080027853A (ko) 2008-03-28
EP2535337A1 (en) 2012-12-19
RS55929B1 (sr) 2017-09-29
BRPI0613615A2 (pt) 2011-01-18
SI2284167T2 (sl) 2020-03-31
SMAP200800011A (it) 2008-02-27
CA2614334A1 (en) 2007-02-08
NO341930B1 (no) 2018-02-19
NZ564409A (en) 2011-07-29
DK2284167T3 (en) 2017-05-01
EP2284168A2 (en) 2011-02-16
US8829015B2 (en) 2014-09-09
MA29626B1 (fr) 2008-07-01
ES2623608T5 (es) 2020-06-18
KR20130077915A (ko) 2013-07-09
MY148554A (en) 2013-04-30
DK2284167T4 (da) 2020-03-02
TWI406661B (zh) 2013-09-01
ES2386974T3 (es) 2012-09-10
SMP200800011B (it) 2008-02-27
PT2284167T (pt) 2017-05-15
SG163620A1 (en) 2010-08-30
EA013464B1 (ru) 2010-04-30
EA200800201A1 (ru) 2008-06-30
BRPI0613615B1 (pt) 2022-02-08
HRP20170634T4 (hr) 2020-02-07
EP2535337B1 (en) 2017-08-23
NI200800017A (es) 2009-03-03
JP2014221831A (ja) 2014-11-27
HRP20120573T1 (hr) 2012-08-31
AU2011202047A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
PE20070214A1 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-trifluoreometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida
UY27567A1 (es) Compuestos cristalinos novedosos
MX2008008298A (es) Sal de sulfato de hidrogeno novedosa.
NO20082793L (no) Nye tiofenderivater
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
DE602006010132D1 (de) Zwischenprodukte für die Herstellung von Trans-5-Chlor-2-Methyl-2,3,3a,12b-Tetrahydro-1h-DibenzÄ2,3:6,7ÜOxepinoÄ4,5-cÜPyrrol
NO20076648L (no) Novel thiophene derivatives
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
ECSP045221A (es) Sales de valsartan
EA200801199A1 (ru) Ингибиторы киназы
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
ZA200800471B (en) Methods of altering poppy characteristics
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
AR072139A1 (es) Polimorfos cristalinos de gemcitabina base
ITMI20052301A1 (it) Procedimento per la produzione di matrici attive con funzioni antimicrobiche
ITVR20040093A1 (it) Procedimento per la produzione di una struttura di cassonetto o simili
TH26593S1 (th) แบบหล่อท้องคาน
TH81701S (th) แบบหล่อท้องคาน
ITMC20050003U1 (it) Lente composta per la realizzazione di fondazioni antisismiche.
CL2010000211A1 (es) Formas cristalinas de sal clorhidrato 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil fenil]-3-4-piridin-3-il-pirimidin-2-ilamino)-benzamida; composicion farmaceutica que las comprende; utiles para tratar enfermedades que responden a la inhibicion de proteina quinasa.
ITPD20050150A1 (it) Macchina per la produzione di tagliatelle, lasagne o simili
RU2007102905A (ru) Глазурь
JP2004226417A5 (es)
RU2002116467A (ru) Средство для лечения экземы
TH81130B (th) อิฐบล็อก

Legal Events

Date Code Title Description
FC Refusal